ASCO 2024 | The role of OSSS in treatment decisions for patients with stage MS neuroblastoma

Leonora Slatnick • 1 Jun 2024

ASCO 2024

Neuroendocrine Tumor

Leonora Slatnick, MD, University of Utah, Salt Lake City, UT, comments on a prospective trial (NCT02176967) examining the use of the Organ System Severity Score (OSSS) in managing patients with newly diagnosed stage MS neuroblastoma (NBL). Results indicate that an OSSS of 0 at diagnosis can identify patients suitable for safe observation, with no progression in organ dysfunction over a median follow-up of 36 months. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.